Lever
Lifestyle
- Reduce alcohol intake
- Maintain healthy weight
- Regular exercise
- Avoid hepatotoxic substances
Blutwerte · Marker
ALT (GPT)
Alanin-Aminotransferase · ALAT · GPT · SGPT
Leberwerte
- Einheit:
- IU/L
- Abbreviation
- ALT / GPT
ALT quantifies the enzyme alanine aminotransferase, which is involved in amino acid metabolism and is indicative of liver cell integrity.
Reference Ranges
Reference
7–56IU/L
7
10
30
56
LowNormalHigh
Reference
Optimal
Unit · IU/LReference ranges can vary slightly between laboratories. Fasting is not required, but recent exercise may affect results.
Overview
Übersicht
ALT (GPT), or Alanine Aminotransferase, is an enzyme primarily found in the liver. It plays a crucial role in the conversion of alanine, an amino acid, into pyruvate, a key intermediate in cellular energy production. ALT is released into the bloodstream when liver cells are damaged, making it a useful marker for liver health. Clinically, elevated ALT levels are indicative of liver injury or inflammation, often associated with conditions such as hepatitis, fatty liver disease, and alcohol-related liver damage. It is also used to monitor the progression of liver diseases and the effectiveness of treatments. For athletes and biohackers, maintaining optimal ALT levels is important as it reflects overall liver health, which is essential for metabolic efficiency and detoxification processes. However, intense physical activity can transiently elevate ALT levels, potentially confounding interpretations. Factors such as time of day, fasting status, and recent exercise can influence ALT measurements, necessitating standardized testing conditions for accurate assessment.
Klinische Bedeutung
Elevated ALT levels suggest liver damage or inflammation, commonly seen in hepatitis, fatty liver disease, and alcohol-related liver injury. Low ALT levels are less common and may not be clinically significant.
Dynamics
Trend Interpretation
Rising Values
Progressively rising ALT levels suggest worsening liver function; re-test in 4 weeks if outside optimal range.
Falling Values
Falling ALT levels may indicate improving liver health or resolution of an acute liver insult.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Liver disease
- Alcohol consumption
- Hepatitis
- Obesity
- Medications
Cause
Low Levels
- Vitamin B6 deficiency
- Severe liver damage
- Uremia
- Malnutrition
- Hypothyroidism
Protocol
How to Optimize
Lever
Nutrition
- Increase antioxidant-rich foods
- Consume omega-3 fatty acids
- Include cruciferous vegetables
- Limit processed foods
Lever
Supplementation
- Milk thistle
- N-acetylcysteine
- Vitamin E
Note:
Consult a healthcare provider before starting any supplementation, especially if liver disease is suspected.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
ALT levels can vary throughout the day; morning tests are recommended for consistency.
Testing Frequency
Annually for healthy adults, more frequently if liver disease is present.
Interfering Factors
- Recent intense exercise
- Certain medications
- Alcohol consumption
Related Peptides & Hormones
Igf 1
hormone or peptideCorrelated with
Open Research Questions
Current research suggests that the reference ranges and optimal targets for ALT (GPT) in various clinical contexts, such as liver disease and alcohol-related organ damage, remain debated, particularly regarding confounding factors like age, sex, and coexisting conditions. Researchers have not yet established standardized guidelines for interpreting ALT levels in specific populations, such as those with sarcoidosis or glycogen storage disease. Unanswered clinical questions include the significance of ALT elevation in asymptomatic patients and its role in monitoring treatment efficacy.
49 Research Publications
582
Total Citations
30
Human/RCT
2.7
Avg. Influence
2025
Latest
Sort
Filter
01Top
#01
A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19).
ReviewInfluence6.0
150
This meta-analysis examined biomarkers associated with the severity of COVID-19. Researchers found that ALAT levels were significantly higher in severe cases compared to non-severe cases. The study indicates that ALAT, among other biomarkers, may help in prognostic risk stratification.
02Top
#02
Use of enzymes for the diagnosis of alcohol-related organ damage.
ReviewInfluence3.0
88
This study reviewed the use of serum enzymes in diagnosing alcohol-related organ damage. Researchers found that elevated ALAT levels can indicate alcohol-induced liver injury, particularly when combined with other enzyme markers. The study emphasizes the need for a combination of tests for accurate diagnosis.
03Top
#03
Dietary management in glycogen storage disease type III: what is the evidence?
ReviewInfluence3.0
49
This study focused on dietary management in children with glycogen storage disease type III. Researchers observed that monitoring laboratory parameters, including ALAT, is critical for managing fasting intolerance and preventing complications. The findings suggest that over-treatment with carbohydrates could be harmful.
04
#04
Sarcoidosis of the liver: to treat or not to treat?
ReviewInfluence2.0
45
This study investigated the effects of ursodeoxycholic acid (UDCA) on liver function in patients with hepatic sarcoidosis. Researchers found that serum liver tests improved in patients treated with UDCA compared to those receiving no treatment or corticosteroids. The results support the use of UDCA in symptomatic patients with liver involvement.
05
#05
Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial.
Human
43
In a randomized controlled trial, researchers tested ursodeoxycholic acid (UDCA) for intrahepatic cholestasis of pregnancy, finding a significant reduction in ALAT levels after treatment. The study involved 20 pregnant women and demonstrated that UDCA improved liver function without adverse effects on pregnancy outcomes.
06
#06
Intrahepatic cholestasis in nonalcoholic fatty liver disease.
HumanInfluence1.0
35
This study examined the frequency of intrahepatic cholestasis in patients with non-alcoholic fatty liver disease (NAFLD) and found that those with cholestasis had significantly higher ALAT levels. Researchers included 163 patients and concluded that cholestasis correlates with more severe liver inflammation and fibrosis.
07
#07
Hypomagnesaemia and muscle electrolytes and metabolites.
Human
28
This study assessed muscle function and laboratory parameters in patients with hypomagnesaemia. Researchers found elevated liver enzymes, including ALAT, in some cases, indicating liver damage. The study highlights the relationship between magnesium levels and muscle performance.
08
#08
Performance of serum biomarkers reflective of different pathogenic processes in systemic sclerosis-associated interstitial lung disease.
Human
22
Researchers compared serum biomarkers in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) and found that elevated ALAT levels were associated with the disease's presence. The study included 225 patients and highlighted the importance of various biomarkers in assessing SSc-ILD progression.
09
#09
Leptospirosis in elderly patients.
HumanInfluence3.0
16
This study analyzed clinical manifestations of leptospirosis in elderly patients, finding slightly elevated ALAT levels among those with severe forms of the disease. Researchers observed that 80% of the cases were severe, with a high mortality rate, emphasizing the need for prompt treatment.
10
#10
Covid-19: contribution of clinical characteristics and laboratory features for early detection of patients with high risk of severe evolution.
Human
15
This study aimed to identify clinical and laboratory predictors of severe COVID-19. Researchers found that elevated ALT levels, among other laboratory features, were associated with worse outcomes in hospitalized patients. The study provides insights into potential early warning signs for severe disease progression.
Clinical Trials (2)
2
Total Trials
82
Total Enrolled
A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors
Sponsor
Pfizer
Enrollment
40
Started
2014
Primary outcome
Number of Participants With Dose-limiting Toxicities (DLT) (Part 1)
NeoplasmsBreast Cancer
Safety Escalating Repeat IV, in Stroke Patients
Sponsor
GlaxoSmithKline
Enrollment
42
Started
2009
Primary outcome
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
Ischaemic Attack, Transient
Publication Trend
Research publications about ALT (GPT) over time
10totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer